Literature DB >> 35389266

Region-Specific Hepatitis B Virus Genome Exposure from Nucleocapsid Modulated by Capsid Linker Sequence and Inhibitor: Implications for Uncoating.

Ji Xi1, Xiuji Cui1, Kuancheng Liu1, Haitao Liu1, Joseph Wang1, Jianming Hu1.   

Abstract

Hepatitis B virus (HBV) contains a partially double-stranded, relaxed circular (RC) DNA genome synthesized within a nucleocapsid (NC) in the host cell cytoplasm. The release of RC DNA from the NC, in an ill-defined process called uncoating, to the nucleus is required for its conversion to the covalently closed circular (CCC) DNA, the viral episome serving as the transcriptional template for all viral RNAs necessary for replication and, thus, essential for establishing and sustaining viral infection. In efforts to better understand uncoating, we analyzed HBV core (HBc) mutants that show various levels of nuclear CCC DNA but little to no cytoplasmic RC DNA. We found that RC DNA could be synthesized by these mutants outside the cell, but in contrast to the wild type (wt), the mutant NCs were unable to protect RC DNA from digestion by the endogenous nuclease(s) in cellular lysates or exogenous DNase. Subcellular fractionation suggested that the major RC DNA-degrading activity was membrane associated. Digestion with sequence-specific and nonspecific DNases revealed the exposure of specific regions of RC DNA from the mutant NC. Similarly, treatment of wt NCs with a core inhibitor known to increase CCC DNA by affecting uncoating also led to region-specific exposure of RC DNA. Furthermore, a subpopulation of untreated wild type (wt) mature NCs showed site-specific exposure of RC DNA as well. Competition between RC DNA degradation and its conversion to CCC DNA during NC uncoating thus likely plays an important role in the establishment and persistence of HBV infection and has implications for the development of capsid-targeted antivirals. IMPORTANCE Disassembly of the hepatitis B virus (HBV) nucleocapsid (NC) to release its genomic DNA, in an ill-understood process called uncoating, is required to form the viral nuclear episome in the host cell nucleus, a viral DNA essential for establishing and sustaining HBV infection. The elimination of the HBV nuclear episome remains the holy grail for the development of an HBV cure. We report here that the HBV genomic DNA is exposed in a region-specific manner during uncoating, which is enhanced by mutations of the capsid protein and a capsid-targeted antiviral compound. The exposure of the viral genome can result in its rapid degradation or, alternatively, can enhance the formation of the nuclear episome, thus having a major impact on HBV infection and persistence. These results are thus important for understanding fundamental mechanisms of HBV replication and persistence and for the ongoing pursuit of an HBV cure.

Entities:  

Keywords:  CCC DNA; antiviral; capsid; cccDNA; covalently closed circular DNA; hepadnavirus; hepatitis B virus; nuclease; nucleocapsid; uncoating

Mesh:

Substances:

Year:  2022        PMID: 35389266      PMCID: PMC9044944          DOI: 10.1128/jvi.00399-22

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  56 in total

1.  Reverse transcription-associated dephosphorylation of hepadnavirus nucleocapsids.

Authors:  David H Perlman; Eric A Berg; Peter B O'connor; Catherine E Costello; Jianming Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-10       Impact factor: 11.205

2.  Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication.

Authors:  Y T Lan; J Li; W Liao; J Ou
Journal:  Virology       Date:  1999-07-05       Impact factor: 3.616

3.  Regulation of multiple stages of hepadnavirus replication by the carboxyl-terminal domain of viral core protein in trans.

Authors:  Kuancheng Liu; Laurie Ludgate; Zhenghong Yuan; Jianming Hu
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

4.  Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.

Authors:  David H Nguyen; Suryaram Gummuluru; Jianming Hu
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

5.  Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation.

Authors:  Haitao Guo; Dong Jiang; Tianlun Zhou; Andrea Cuconati; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

Review 6.  Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.

Authors:  Daniel N Clark; Jianming Hu
Journal:  Antiviral Res       Date:  2015-09-25       Impact factor: 5.970

7.  Cell-Free Hepatitis B Virus Capsid Assembly Dependent on the Core Protein C-Terminal Domain and Regulated by Phosphorylation.

Authors:  Laurie Ludgate; Kuancheng Liu; Laurie Luckenbaugh; Nicholas Streck; Stacey Eng; Christian Voitenleitner; William E Delaney; Jianming Hu
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

8.  Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes.

Authors:  Eloi R Verrier; Seung-Ae Yim; Laura Heydmann; Houssein El Saghire; Charlotte Bach; Vincent Turon-Lagot; Laurent Mailly; Sarah C Durand; Julie Lucifora; David Durantel; Patrick Pessaux; Nicolas Manel; Ivan Hirsch; Mirjam B Zeisel; Nathalie Pochet; Catherine Schuster; Thomas F Baumert
Journal:  Hepatology       Date:  2018-07-10       Impact factor: 17.298

9.  HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways.

Authors:  Fang Guo; Qiong Zhao; Muhammad Sheraz; Junjun Cheng; Yonghe Qi; Qing Su; Andrea Cuconati; Lai Wei; Yanming Du; Wenhui Li; Jinhong Chang; Ju-Tao Guo
Journal:  PLoS Pathog       Date:  2017-09-25       Impact factor: 6.823

Review 10.  Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application.

Authors:  Jianming Hu; Kuancheng Liu
Journal:  Viruses       Date:  2017-03-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.